… the MUC5B genotype and interferon-γ1b treatment, it is … survival is dependent on interferon-γ1b
treatment. However, … of these patients were treated with interferon-γ1b. Further studies …

… of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis. …
of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis. …

… of interferon-γ1b on biomarker expression in patients with idiopathic pulmonary fibrosis. …
in lymphocytes from bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis. …

… is important for lung regenerative events and is significantly perturbed in pulmonary fibrosis.
… activity may represent a potential beneficial strategy for treating human pulmonary fibrosis. …

… , antifibrotic agents are expected to be useful for the treatment of patients with idiopathic
pulmonary fibrosis. … IFN-γ (interferon-γ1b) had been undergoing clinical trials in patients with …

… pilot studies that evaluated new antifibrotic agents to treat IPF. Agents such as etanercept,
a human tumor necrosis factor receptor, interferon-γ1b, and tyrosine kinase inhibitors such as …

… treatment in the INSPIRE trial highlight the need for large, well designed studies in patients
with idiopathic pulmonary fibrosis … in patients with idiopathic pulmonary fibrosis. Am J Respir …

… Background: Idiopathic pulmonary fibrosis (IPF) is a rapidly lethal disease characterized by
anarchic, progressive fibrosis. Pulmonary fibrosis is the result of interactions between many …

… to moderate idiopathic pulmonary fibrosis (FVC >50% and DL CO >30%), a trend toward
lower mortality was seen in IFN-γ1b-treated patients compared with placebo-treated patients. …

… The percentages of patients using steroids, azathioprine, colchicine, cyclophosphamide,
interferon-γ1b, or anticoagulants for longer than 3 months and those receiving only …